Navigation Links
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
Date:7/11/2012

LONDON, July 12, 2012 /PRNewswire/ --


THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF ANY OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY NEW ORDINARY SHARES, NOR SHALL IT (OR ANY PART OF IT), OR THE FACT OF ITS DISTRIBUTION, FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION WITH OR ACT AS ANY INDUCEMENT TO ENTER INTO, ANY CONTRACT OR COMMITMENT WHATSOEVER WITH RESPECT TO THE PROPOSED SHARE CAPITAL REORGANISATION, SUBSCRIPTION, ISSUE OF CONVERTIBLE LOAN NOTE, OPEN OFFER OR ESTABLISHMENT OF AN EQUITY FINANCE FACILITY OR OTHERWISE. THIS ANNOUNCEMENT IS NOT A CIRCULAR AND INVESTORS SHOULD NOT SUBSCRIBE FOR OR PURCHASE ANY NEW ORDINARY SHARES REFERRED TO IN THIS ANNOUNCEMENT EXCEPT SOLELY ON THE BASIS OF INFORMATION IN THE CIRCULAR EXPECTED TO BE PUBLISHED TODAY. COPIES OF THE CIRCULAR WILL, FOLLOWING PUBLICATION, BE AVAILABLE FROM SILENCE THERAPEUTICS' OFFICES AT THE ROYAL INSTITUTION OF GREAT BRITAIN, 21 ALBEMARLE STREET, LONDON, W1S 4BS.

THE SECURITIES MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, UNLESS REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR PURSUANT TO AN EXEMPTION FROM SUCH REGISTRATION. NO PUBLIC OFFERING OF THE SECURITIES DISCUSSED HEREIN IS BEING MADE IN THE UNITED STATES AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFERING OF SECURITIES FOR SALE IN THE UNITED STATES AND THE COMPANY DOES NOT CURRENTLY INTEND TO REGISTER ANY SECURITIES UNDER THE SECURITIES ACT. THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Silence Therapeutics Additional Listing
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
6. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
8. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
9. United Therapeutics Announces Additional $100 Million Share Repurchase Program
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Based on the revenues ... imaging market is dominated by four major players ... market. These players include GE Healthcare (U.K.), Siemens ... , Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html ... can be attributed to its strong product portfolio, ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... -- Vermillion, Inc. (NASDAQ: VRML ), a bio-analytic ... next step in its expanded strategy to rebuild the ... naming of current Chief Operating Officer, Valerie Palmieri ... Chairman of the Board and CEO James LaFrance ... are effective January 1, 2015. "Jim and ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4
... Inc. (Amex:,SGN) announced that it has provided notification to ... withdraw its common stock,from listing and trading on AMEX ... Company Guide. An application to quote and trade Signalife,s ... the OTCBB, on which medium the,shares traded prior to ...
... 8 ThirdBiotech Inc.,( http://www.thirdbiotech.com ), ... today announced that Kemeta, a medical ... manufacture of breath acetone sensing,technology and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070911/LATU119LOGO ), ...
... HARBIN, China, Aug. 8 /Xinhua-PRNewswire-FirstCall/ -- China ... Yingxia" or "the,Company"), a leading provider in ... and distribution of organic nutritional food,products, supplements, ... Republic,of China ("PRC"), announced today it will ...
Cached Biology Technology:Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB 2Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB 3Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB 4ThirdBiotech Announces Kemeta as Newest Sponsor 2China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results 2
(Date:11/18/2014)... 17, 2014 The Parenteral Drug Association (PDA) today ... will speak and at least seven more will participate in ... Omni Shoreham Hotel in Washington D.C. , ... have significant support from the regulatory agencies in ... in our effort to help advance the use of ...
(Date:11/15/2014)... 2014  While we may still be a few years ... "Star Trek" to gain instant access to all that ailed ... smartphones and tablets for monitoring and measuring our health are ... may seem a tad Orwellian to some, but a new ... these technological opportunities into their healthcare regime. These ...
(Date:11/11/2014)...  Forensicon, Inc., a Chicago -based ... the promotion of Yaniv Schiff from Senior ... Schiff,s new role as Director, he will lead company ... examiners and provide leadership within the company,s digital forensics ... Schiff joined Forensicon in 2006 ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... Center have identified how nanoparticles from diesel exhaust damage lung ... for people susceptible to airway disease. The scientists ... the genetic make-up of the affected individual. "We ... in polluted areas and why others don,t," said lead author ...
... young people engage in, has associated adverse health risks ... controlling overall alcohol usage, states an editorial in ... link only) http://www.cmaj.ca/embargo/cmaj110029.pdf . "Given the many ... we need a national strategy for controlling overall alcohol ...
... eating a big breakfast help weight loss or is ... confusing but new research published in BioMed Central,s open ... through these apparently contradictory reports. Dr Volker Schusdziarra, ... study on over 300 people who were asked to ...
Cached Biology News:Findings on pollution damage to human airways could yield new therapies 2
...
Bovine Serum...
Healthy animals 10-32 weeks of age, mixed gender and breed; collected on wet ice following USDA guidelines, using Alsevers solution at 1:2 dilution...
... Kits for Sequencing allow 5-minute cloning and subsequent ... Cloning vectors with primer sites located as close ... insertion site. This minimizes the amount of vector ... the sequence of your insert.vectors are available. The ...
Biology Products: